Partnership strategy

Cyotvac is actively pursuing partnership with pharmaceutical companies, universities, patient organizations and other relevant parties that will promote our ambition to treat cancer diseases.

The company is confident that, exploiting Cytovac’s scientific basis and results, in combination with a future commercial partner expertise in business and development strategies may take both parties to new successful levels and dimensions.

Provided that the positive clinical data already seen in clinical trials is confirmed in the ongoing clinical phase II study in GBM brain cancer, commercialization of the ALECSAT therapy may start by the end of 2019 in collaboration with partners.

Also, clinical phase II studies within pancreatic and prostate cancer may commence in a partnership structure.

ALECSAT – a unique platform

As ALECSAT is manufactured on the basis of a blood donation from the individual patient – without the use of advanced technology – and no tumour tissue, no foreign proteins or peptides are involved in the production process. This combined with a relatively inexpensive procedure and rapid production times has led to a commercially viable, efficient and scalable production process.

It is moreover an advantage that the ALECSAT immunotherapy may also be used in combination with other immunotherapeutic cancer treatment principles or be combined with existing cancer treatments for the purpose of obtaining optimal treatment.

ALECSAT is manufactured on the basis of a blood donation from the individual patient – without the use of advanced and expensive techniques – leading to a rapid and easy production procedure.

Orphan Drug Designation

There are a number of commercial advantages associated with the fact that Cytovac’s ALECSAT therapy project targeted at brain cancer has achieved Orphan Drug Designation.

The potential for obtaining faster marketing approval of ALECSAT that will result in longer time on the market.

Moreover, orphan drug designation also gives market exclusivity; 10-years in the EU market – and 7 years in USA. Furthermore, certain countries operate with reduced tax and reduced charges from regulatory authorities.


Patent protection of the ALECSAT therapy has been issued in 36 countries. Also Cytovac’ dendritic-cell production technology and a specialised cell-production bottle are being protected by pending patent applications. Altogether, this ensures a strong IP protection of ALECSAT’s market position.


A summary of the ALECSAT advantages

Adoptive Celle Therapies such as the ALECSAT therapy are well tolerated and have very few side effects.

ALECSAT has specificity for and recognises many different cancer-specific antigens.

ALECSAT will also be efficacious in patients with extremely inhibited immune defence mechanisms.

ALECSAT has three potential and combined modes of action:

  1. Direct cancer-cell destruction by way of the CTLs and NK cells administered via injection.
  2. Continued and persistent cancer-cell destruction as the ALECSAT cells will continue to divide into more new fighting cells.
  3. Reactivation of the patient’s immune defence may also lead to continued and persistent destruction of new cancer cells; potentially, also in case of recurrence of the disease.

The Danish Cancer Society


Bárður Sigurgeirsson MD, PhD. Assistant Professor of Dermatology University of Iceland


Arkadiusz Dudek, MD, PhD Professor
University of Illinois Cancer Center